Galmed Pharmaceuticals (GLMD) Accounts Payables (2013 - 2026)
Galmed Pharmaceuticals (GLMD) posted quarterly Accounts Payables of $1.7 million for Q1 2026, up 31.8% year-over-year from $1.3 million in Q1 2025, and down 13.93% quarter-over-quarter from $2.0 million in Q4 2025.
Galmed Pharmaceuticals (GLMD) Accounts Payables (2013 - 2026) Analysis & Trends
Galmed Pharmaceuticals' Accounts Payables history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 31.8% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 31.8% YoY), while the FY2025 annual figure was $2.0 million, up 9438.1% from the prior year.
- Accounts Payables for Q1 2026 stood at $1.7 million, down from $2.0 million in the prior quarter.
- The five-year high for Accounts Payables was $4.8 million in Q1 2022, with the low at $21000.0 in Q4 2024.
- The 5-year median for Accounts Payables is $1.7 million (2025), against an average of $1.9 million.
- The sharpest annual moves came in 2024 and 2025: Accounts Payables sank 98.88% in 2024, then surged 9438.1% in 2025.
- Galmed Pharmaceuticals' Accounts Payables stood at $2.6 million in 2022, then declined by 26.6% to $1.9 million in 2023, then tumbled by 98.88% to $21000.0 in 2024, then soared by 9438.1% to $2.0 million in 2025, then declined by 13.93% to $1.7 million in 2026.
- Business Quant data shows GLMD's Accounts Payables at $1.7 million in Q1 2026, $2.0 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | 1.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.72 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 1.67 Mn |
| Jun 30, 2025 | 1.37 Mn |
| Mar 31, 2025 | 1.31 Mn |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 1.34 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 1.38 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Sep 30, 2023 | 1.47 Mn |
| Jun 30, 2023 | 2.14 Mn |
| Mar 31, 2023 | 106,000.00 |
| Dec 31, 2022 | 2.56 Mn |
| Sep 30, 2022 | 4.75 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 4.84 Mn |
| Dec 31, 2021 | 4.87 Mn |
| Sep 30, 2021 | 5.23 Mn |
| Jun 30, 2021 | 5.63 Mn |